PF407 TREATMENT-FREE REMISSION IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA FOLLOWING FIRST-LINE DASATINIB, 1ST DADI/IMIDAS4

Autor:	K. Murai, Y. Kakinoki, Y. Ishida, T. Kitawaki, H. Shibayama, M. Hayakawa, Hiroaki Tanaka, A. Takaori, H. Nakamae, T. Hosoki, A. Kawaguchi, T. Ikezoe, J. Sakamoto, N. Takezako, T. Nishimoto, K. Ikeda, S. Kimura, J. Imagawa, N. Uoshima, M. Shindo, M. Okada, T. Sato, S. Kowata, M. Hino, R. Watanabe, T. Kobayashi, T. Kumagai, H. Ureshino
Rok vydání:	2019
Předmět:	Dasatinib Oncology medicine.medical_specialty business.industry Internal medicine First line medicine In patient Hematology medicine.disease business medicine.drug Chronic myelogenous leukemia
Zdroj:	HemaSphere. 3:155-156
ISSN:	2572-9241
DOI:	10.1097/01.hs9.0000559840.07660.1c
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::2a7041176667607db3f04c778427fe86 https://doi.org/10.1097/01.hs9.0000559840.07660.1c Zobrazit plný text záznamu Plný text